Modelli di dati selezionati

Devi effettuare il log in per selezionare i modelli di dati da scaricare per successive analisi

24 Risultati di ricerca.
rilevanza Valutazione Più recente Meno recente

Oral Topotecan as Radiosensitizing Agent in Patients with Rectal Cancer; NCT00158886 - Response Assessment

- 20/08/19 - 1 modulo, 4 itemgroups, 12 elementi, 1 linguaggio
Itemgroups: Administrative documentation, TNM clinical staging, Rectal Carcinoma, Pathological staging, Rectal Carcinoma, Sphincter, Preservation technique
Study ID: 104864/517 Clinical Study ID: 104864/517 Study Title: A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00158886 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Topotecan + Radiation therapy Trade Name: N/A Study Indication: Rectal Cancer, Carcinoma, Renal Cell

Colorectal Cancer NCT00077233 Response - CALGB: 80203 Solid Tumor Evaluation Form - 2101473v3.0 - CALGB: 80203 Solid Tumor Evaluation Form

- 09/01/15 - 1 modulo, 1 ItemGroup, 21 elementi, 1 linguaggio
ItemGroup: CCRR MODULE
CALGB: 80203 Solid Tumor Evaluation Form Fluorouracil and Leucovorin Plus Either Irinotecan or Oxaliplatin With or Without Cetuximab in Treating Patients With Previously Untreated Metastatic Adenocarcinoma of the Colon or Rectum Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=BB6E5D42-FA40-4373-E034-0003BA12F5E7

Kidney Cancer NCT01120249 Response - Southwest Oncology Group S0931 Recurrence Assessment Form (Form #46940) - 2998562v1.0 - Southwest Oncology Group S0931 Recurrence Assessment Form (Form #46940)

- 20/09/21 - 1 modulo, 4 itemgroups, 24 elementi, 1 linguaggio
Itemgroups: Header Module, Clinical Assessment, Notice of Recurrence, COMMENTS
Southwest Oncology Group S0931 Recurrence Assessment Form (Form #46940) Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=7E26385C-8CD8-C34F-E040-BB89AD434A8D

Pancreatic Cancer NCT00058149 Response - E6201 Cover Page for Supplemental Form - 2075318v3.0 - E6201 Cover Page for Supplemental Form

- 09/01/15 - 1 modulo, 4 itemgroups, 12 elementi, 1 linguaggio
Itemgroups: Header, On Treatment, Off Treatment, CCRR MODULE
E6201 Cover Page for Supplemental Form A Phase III, Randomized Study of Gemcitabine (Fixed-Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus Gemcitabine (Fixed-Dose Rate Infusion) Versus Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B1B0ADEE-BA19-4B20-E034-0003BA12F5E7

Pancreatic Cancer NCT00058149 Response - E6201 Cover Page for RECIST Forms - 2075205v3.0 - E6201 Cover Page for RECIST Forms

- 09/01/15 - 1 modulo, 4 itemgroups, 13 elementi, 1 linguaggio
Itemgroups: Header, On Treatment, Off Treatment, CCRR MODULE
E6201 Cover Page for RECIST Forms A Phase III, Randomized Study of Gemcitabine (Fixed-Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus Gemcitabine (Fixed-Dose Rate Infusion) Versus Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B1B164EC-ED7F-4A7F-E034-0003BA12F5E7

Pancreatic Cancer NCT00058149 Response - E6201 Cover Page for Adverse Event Form - 2075284v3.0 - E6201 Cover Page for Adverse Event Form

- 09/01/15 - 1 modulo, 4 itemgroups, 12 elementi, 1 linguaggio
Itemgroups: Header, On Treatment, Off Treatment, CCRR MODULE
E6201 Cover Page for Adverse Event Form A Phase III, Randomized Study of Gemcitabine (Fixed-Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus Gemcitabine (Fixed-Dose Rate Infusion) Versus Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B1B0ABAE-0BB9-4B1E-E034-0003BA12F5E7

Pancreatic Cancer NCT00058149 Response - E6201 Cover Page for Hematology/Chemistry Forms - 2075247v3.0 - E6201 Cover Page for Hematology/Chemistry Forms

- 09/01/15 - 1 modulo, 4 itemgroups, 12 elementi, 1 linguaggio
Itemgroups: Header, On Treatment, Off Treatment, CCRR MODULE
E6201 Cover Page for Hematology/Chemistry Forms A Phase III, Randomized Study of Gemcitabine (Fixed-Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus Gemcitabine (Fixed-Dose Rate Infusion) Versus Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B1B0A8C1-ED1A-4B19-E034-0003BA12F5E7

Lung Cancer NCT00632853 Treatment - CALGB: 30610 Treatment and Response Form - 2688627v1.0 - CALGB: 30610 Treatment and Response Form

- 08/01/15 - 1 modulo, 5 itemgroups, 35 elementi, 1 linguaggio
Itemgroups: Header, Survival Date, Treatment Data, Response Data, Footer
CALGB: 30610 Treatment and Response Form Three Different Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=3C3834F7-372A-2795-E044-0003BA3F9857

Lung Cancer NCT00049543 Response - Form 9 - Relapse/ Progressive Disease Report - 2034459v3.0 - Form 9 - Relapse/ Progressive Disease Report

- 09/01/15 - 1 modulo, 8 itemgroups, 50 elementi, 2 lingue
Itemgroups: 1. PATIENT INFORMATION, Radiology, 3. DISEASE STATUS, NCIC CTG use only, 4. RECURRENCE TABLE, 5. TREATMENT PLAN , 6. COMMENTS, 8. INVESTIGATOR SIGNATURE
Form 9 - Relapse/ Progressive Disease Report Gefitinib in Treating Patients With Non-Small Cell Lung Cancer That Has Been Surgically Removed Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A06B0201-DAB9-5179-E034-080020C9C0E0

Response - PHASE II LUNG CANCER ¿ BASELINE SOLID TUMOR EVALUATION FORM - 2400961v1.0 - PHASE II LUNG CANCER ¿ BASELINE SOLID TUMOR EVALUATION FORM

- 09/01/15 - 1 modulo, 5 itemgroups, 28 elementi, 1 linguaggio
Itemgroups: CRF Header, Form Administration, Target Lesion(s) Baseline Evaluation , Nontarget Lesion(s) Baseline Evaluation, Comments
Phase II Consortium - PHASE II LUNG CANCER - BASELINE SOLID TUMOR EVALUATION FORM Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FFA78C21-8B29-096C-E034-0003BA3F9857

Lung Cancer NCT01336894 Response - ACOSOG-Z4099 Pretreatment RECIST Measurement Form (Arm 2) - 3178401v1.0 - ACOSOG-Z4099 Pretreatment RECIST Measurement Form (Arm 2)

- 09/01/15 - 1 modulo, 3 itemgroups, 11 elementi, 1 linguaggio
Itemgroups: Header Module, Visit, Pretreatment Measurement
ACOSOG-Z4099 Pretreatment RECIST Measurement Form (Arm 2) Surgery With or Without Internal Radiation Therapy Compared With Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Stage I Non-Small Cell Lung Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=986988FF-3289-FDB7-E040-BB89AD4317E3

Adenocarcinoma of the Gastroesophageal Junction NCT01196390 Treatment - RTOG 1010 Post Treatment Response Form (F2) - 3180385v1.0 - RTOG 1010 Post Treatment Response Form (F2)

- 17/09/21 - 1 modulo, 3 itemgroups, 20 elementi, 1 linguaggio
Itemgroups: Header Module, Unnamed 1, Footer Module
RTOG 1010 Post Treatment Response Form (F2) Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=99087049-39B3-FC29-E040-BB89AD43284B

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial